Additive prognostic significance of ejection fraction for ESC risk model in hypertrophic cardiomyopathy patients.
Aged
Cardiomyopathy, Hypertrophic
/ complications
Databases, Factual
Death, Sudden, Cardiac
/ etiology
Decision Support Techniques
Female
Heart Rate
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Predictive Value of Tests
Prognosis
Reproducibility of Results
Retrospective Studies
Risk Assessment
Risk Factors
Stroke Volume
Tachycardia, Ventricular
/ diagnosis
Time Factors
Ventricular Fibrillation
/ diagnosis
Ventricular Function, Left
Ejection fraction
Hypertrophic cardiomyopathy
Prognosis
Risk stratification model
Sudden death
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
03
07
2019
accepted:
23
08
2019
pubmed:
5
9
2019
medline:
27
10
2020
entrez:
5
9
2019
Statut:
ppublish
Résumé
The European Society of Cardiology (ESC) clinical risk model is reported in predicting sudden death of hypertrophic cardiomyopathy (HCM). We examined the validity of this model and investigated the significance of ejection fraction (EF) in predicting the prognosis using ESC risk model in HCM patients. 305 HCM patients (198 males) were followed (median follow-up 4.8 years) for life-threatening arrhythmic events (sudden death, aborted sudden death, sustained VT/VF, appropriate ICD intervention for VT/VF) and were divided using ESC risk model into low- (Group L), intermediate- (Group I) and high- (Group H) risk groups. There was a significant difference in the events rate among the 3 groups (L, 0.9%/year; I, 3.9%/year; H, 6.8%/year; log-rank p < 0.001) in all study patients. Reduced EF (<50%) was identified in 27 (8.9%) cases. There was a significant difference in the events rate among the 3 groups in patients with reduced EF (L, 2.4%/year; I, 4.9%/year; H, 16.1%/year; log-rank p = 0.025). There was a significant difference in the events rate among 2 groups in patients stratified as Group H (preserved EF, 3.1%/year vs. reduced EF, 16.1%/year; log-rank p = 0.041). ESC risk model precisely predicts life-threatening events in patients with HCM. Adding EF to ESC risk model are useful for further risk stratification of life-threatening arrhythmic events.
Identifiants
pubmed: 31482217
doi: 10.1007/s00380-019-01496-w
pii: 10.1007/s00380-019-01496-w
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-398Références
Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P (2000) Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342:365–373
doi: 10.1056/NEJM200002103420601
Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405–412
pubmed: 17652294
Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P (2018) Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 11:e005820
doi: 10.1161/CIRCEP.117.005820
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 35:2010–2020
doi: 10.1093/eurheartj/eht439
Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, Willems R, Michels M (2015) Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 8:829–835
doi: 10.1161/CIRCEP.114.002553
Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS (2015) Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116:757–764
doi: 10.1016/j.amjcard.2015.05.047
Fernandez A, Quiroga A, Ochoa JP, Mysuta M, Casabe JH, Biagetti M, Guevara E, Favaloro LE, Fava AM, Galizio N (2016) Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference Center in South America. Am J Cardiol 118:121–126
doi: 10.1016/j.amjcard.2016.04.021
Magri D, Limongelli G, Re F, Agostoni P, Zachara E, Correale M, Mastromarino V, Santolamazza C, Casenghi M, Pacileo G, Valente F, Musumeci B, Maruotti A, Volpe M, Autore C (2016) Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 102:602–609
doi: 10.1136/heartjnl-2015-308453
O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, Cecchi F, Olivotto I, Kitaoka H, Gotsman I, Carr-White G, Mogensen J, Antoniades L, Mohiddin SA, Maurer MS, Tang HC, Geske JB, Siontis KC, Mahmoud KD, Vermeer A, Wilde A, Favalli V, Guttmann OP, Gallego-Delgado M, Dominguez F, Tanini I, Kubo T, Keren A, Bueser T, Waters S, Issa IF, Malcolmson J, Burns T, Sekhri N, Hoeger CW, Omar RZ, Elliott PM (2018) International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). Circulation 137:1015–1023
doi: 10.1161/CIRCULATIONAHA.117.030437
O'Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, Michels M, Magri D, Autore C, Fernandez A, Ochoa JP, Leong KMW, Varnava AM, Monserrat L, Anastasakis A, Garcia-Pavia P, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Omar RZ, Elliott PM (2019) Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 105:623–631
pubmed: 30366935
Nakagawa S, Okada A, Nishimura K, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Kanzaki H, Kusano K, Yasuda S, Izumi C (2018) Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model among various phenotypes in Japanese patients with hypertrophic cardiomyopathy. Am J Cardiol 122:1939–1946
doi: 10.1016/j.amjcard.2018.08.042
JCS 2018 Guideline on Diagnosis and Treatment of Cardiomyopathies; http://www.j-circ.or.jp/guideline/pdf/JCS2018_tsutsui_kitaoka.pdf . Accessed 06 June 06 2019 (in Japanese)
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, Anderson JL (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126:e354–471
pubmed: 23166211
Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O'Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309:896–908
doi: 10.1001/jama.2013.1363
Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, Elliott PM, McKenna WJ (2005) Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 91:920–925
doi: 10.1136/hrt.2003.031161
Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L, Lofiego C, Boriani G, Prandstraller D, Picchio FM, Branzi A, Rapezzi C (2005) Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46:1543–1550
doi: 10.1016/j.jacc.2005.04.062
Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114:216–225
doi: 10.1161/CIRCULATIONAHA.105.583500
Biagini E, Spirito P, Leone O, Picchio FM, Coccolo F, Ragni L, Lofiego C, Grigioni F, Potena L, Rocchi G, Bacchi-Reggiani L, Boriani G, Prandstraller D, Arbustini E, Branzi A, Rapezzi C (2008) Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol 101:387–392
doi: 10.1016/j.amjcard.2007.09.085
Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011) Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17:459–464
doi: 10.1016/j.cardfail.2011.01.015
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology foundation task force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713
doi: 10.1016/S0735-1097(03)00941-0
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–2796
doi: 10.1161/CIR.0b013e318223e230
JCS-Digest Version (2012) Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circ J 2016;80:753–774
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218
doi: 10.1016/S0735-1097(00)01003-2
Christiaans I, van Engelen K, van Langen IM, Birnie E, Bonsel GJ, Elliott PM, Wilde AA (2010) Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 12:313–321
doi: 10.1093/europace/eup431
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 15:e73–e189
doi: 10.1016/j.hrthm.2017.10.036
Hen Y, Iguchi N, Utanohara Y, Takada K, Machida H, Takara A, Teraoka K, Sumiyoshi T, Takamisawa I, Takayama M, Yoshikawa T (2016) Extent of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 80:950–957
doi: 10.1253/circj.CJ-15-1100
Rosmini S, Biagini E, O'Mahony C, Bulluck H, Ruozi N, Lopes LR, Guttmann O, Reant P, Quarta CC, Pantazis A, Tome-Esteban M, McKenna WJ, Rapezzi C, Elliott PM (2017) Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart 103:300–306
doi: 10.1136/heartjnl-2016-310138
Aizawa Y, Tanimoto Y, Hirata Y, Fujisawa T, Fukuoka R, Nakajima K, Katsumata Y, Nishiyama T, Kimura T, Yuasa S, Kohno T, Kohsaka S, Murata M, Maekawa Y, Furukawa Y, Takatsuki S, Fukuda K (2018) Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy. Keio J Med. https://doi.org/10.2302/kjm.2018-0004-OA
doi: 10.2302/kjm.2018-0004-OA
pubmed: 30606897
Kitaoka H, Kubo T, Okawa M, Hitomi N, Furuno T, Doi YL (2006) Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in rural community. Circ J 70:1543–1549
doi: 10.1253/circj.70.1543
Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106:261–267
doi: 10.1016/j.amjcard.2010.03.020
Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5:535–546
doi: 10.1161/CIRCHEARTFAILURE.112.967026
Hen Y, Iguchi N, Utanohara Y, Takada K, Machida H, Takayama M, Sumiyoshi T (2014) Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 78:929–937
doi: 10.1253/circj.CJ-13-0979
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495
doi: 10.1161/CIRCULATIONAHA.113.007094
Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101:1406–1411
doi: 10.1136/heartjnl-2015-307682
He D, Ye M, Zhang L, Jiang B (2018) Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung 47:122–126
doi: 10.1016/j.hrtlng.2017.10.008
Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels 28:742–749
doi: 10.1007/s00380-012-0300-3
Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ (2008) Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 118:1541–1549
doi: 10.1161/CIRCULATIONAHA.108.781401
Jacoby D, McKenna WJ (2012) Genetics of inherited cardiomyopathy. Eur Heart J 33:296–304
doi: 10.1093/eurheartj/ehr260
Ciampi Q, Betocchi S, Lombardi R, Manganelli F, Storto G, Losi MA, Pezzella E, Finizio F, Cuocolo A, Chiariello M (2002) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 40:278–284
doi: 10.1016/S0735-1097(02)01950-2